Merus BV (MRUS)
followers
·
Follow
1 like
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Sven A. Lundberg |
| Employees: | 37 |
| Web site: | merus.nl |
|
YALELAAN 62, 3584 CM UTRECHT, P7, 3584 CM
31 030 253 8800
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
Please log in first to see chart